









Markets
/
Stocks
/
nasdaq-tovx
/

Theriva Biologics Inc

TOVX

0.220USD

+0.001+0.25%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.27MMarket Cap

0.11P/E TTM



Theriva Biologics Inc

0.220

+0.001+0.25%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Theriva Biologics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Theriva Biologics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 205 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Theriva Biologics Inc's Score

Industry at a Glance

Industry Ranking

205 / 392

Overall Ranking

399 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Theriva Biologics Inc Highlights

StrengthsRisks

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is 0.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 861.13K shares, decreasing 24.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 255.73K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.45.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+3900.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Theriva Biologics Inc is 7.10, ranking 159 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.10

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.74

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Theriva Biologics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Theriva Biologics Inc is 7.14, ranking 164 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.11, which is 23.34% below the recent high of 0.13 and 20365.04% above the recent low of -21.62.

Score

Industry at a Glance

Previous score

7.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 205/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Theriva Biologics Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.000

Target Price

+3900.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Theriva Biologics Inc

TOVX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Theriva Biologics Inc is 1.84, ranking 382 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.24 and the support level at 0.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.84

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Neutral

RSI(14)

56.266

Neutral

STOCH(KDJ)(9,3,3)

75.466

Buy

ATR(14)

0.018

Low Volatility

CCI(14)

170.944

Buy

Williams %R

0.000

Overbought

TRIX(12,20)

-0.538

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.191

Buy

MA10

0.192

Buy

MA20

0.197

Buy

MA50

0.209

Buy

MA100

0.285

Sell

MA200

0.419

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Theriva Biologics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.41%, representing a quarter-over-quarter increase of 151.88%. The largest institutional shareholder is The Vanguard, holding a total of 255.73K shares, representing 0.72% of shares outstanding, with 156.29% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Jeffrey Matthew Gryga Irrevocable Trust

739.21K

The Vanguard Group, Inc.

Star Investors

16.38K

+17.46%

UBS Financial Services, Inc.

22.91K

+2291200.00%

Ikarian Capital LLC

120.03K

Two Sigma Investments, LP

89.12K

+400.17%

Virtu Americas LLC

36.78K

+6.63%

Jane Street Capital, L.L.C.

36.77K

Boothbay Fund Management, LLC

35.60K

XTX Markets LLC

32.90K

+91.42%

Geode Capital Management, L.L.C.

28.21K

+51.65%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Theriva Biologics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.